Table 2.
In vitro antiplasmodial activity of the prepared SLNs
| Samples | D6 IC50 (based on gross weight of SLNs) | D6 IC50 (based on actual CQ concentration at 25 and 21% DL for CQ-SLN and CQ-Hep-SLN) | D6 IC50 (Based on actual CQ concentration at 25 and 21% DL and in vitro drug release at 66 h for CQ-SLN (80%) and CQ-Hep-SLN (50%) | W2 IC50 |
|---|---|---|---|---|
| Heparin Na salt | > 100 µg/mL | – | – | > 100 µg/mL |
| SLN | > 100 µg/mL | – | – | > 100 µg/mL |
| CQ-SLN | 23.75 ± 3.24 ng/mL | 5.94 ± 0.18 ng/mL | 4.752 ± 0.144 ng/mL | > 400 ng/mL |
| Hep-SLN | 12.98 ± 1.62 µg/mL | – | > 100 µg/mL | |
| CQ-Hep-SLN | 22.97 ± 2.58 ng/mL | 4.82 ± 0.54 ng/mL | 2.41 ± 0.27 ng/mL | > 400 ng/mL |
| CQ drug | 5.81 ± 0.18 ng/mL | 5.81 ± 0.18 ng/mL | 5.81 ± 0.18 ng/mL | 58.71 ± 2.67 ng/mL |